<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363431">
  <stage>Registered</stage>
  <submitdate>2/01/2013</submitdate>
  <approvaldate>11/01/2013</approvaldate>
  <actrnumber>ACTRN12613000031763</actrnumber>
  <trial_identification>
    <studytitle>Statin Therapy in Ischemia-Reperfusion Injury during coronary artery bypass grafting.</studytitle>
    <scientifictitle>Statin therapy in Ischemia-Reperfusion Injury: A randomised trial to evaluate the effect of high dose rosuvastatin on myocardial infarct size post  coronary artery bypass grafting (CABG). </scientifictitle>
    <utrn>U1111-1138-1724 </utrn>
    <trialacronym>STIR (CABG)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post CABG ischemia reperfusion injury (IRI)</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rosuvastatin 40mgs orally at 36 hours and 12 hours pre CABG and then rosuvastatin 40 mgs daily for 7 days post CABG.</interventions>
    <comparator>The control group will receive standard care as per normal clinical practice for the treatment of CABG patients which will include being prescribed a medication from the statin group but not at as large a dose as this would have precluded them from being randomised into the study.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myocardial Infarct (MI) size as assessed by CMR late gadolinium-enhancement</outcome>
      <timepoint>At Baseline (up to 30 days before CABG) and then 5-10 days post CABG surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical markers of myocardial injury will be assessed by calculating the total area under the curve of the cardiac enzyme levels (CK, CKMB and Hs Troponin T) taken over an 120 hour period.</outcome>
      <timepoint>Baseline(0 Hours) pre CABG, 6, 12, 24, 48, 72 and 120 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients who are scheduled to undergo elective on-pump CABG with or without aortic valve replacement.
For patients on statins pre-CABG, statin dose must be unchanged for 30 days pre-CABG.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Standard CMR contra-indications
Known intolerance to statins
Renal (eGFR &lt;45mls/min) and hepatic impairment
Emergency CABG
Mitral or tricuspid valve repair or replacement
Off-pump CABG
Patients who are Filipino, Chinese, Japanese, Korean or Vietnamese
Patients on cyclosporine, gemfibrozil or fisidic acid
Patients who are already on rosuvastatin or atorvastatin 80 mgs pre-CABG
Re-do surgery

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/02/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>5001 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>South Australian Health and Medical Research Institute</primarysponsorname>
    <primarysponsoraddress>Level 9, 121 King William Street, PO Box 11060
Adelaide SA 5001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>South Australian Health and Medical Research Institute</fundingname>
      <fundingaddress>Level 9, 121 King William Street, PO Box 11060
Adelaide SA 5001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to ascertain whether giving high doses of a cholesterol lowering drug (statin) can reduce the amount of damage caused to the heart by having a lack of oxygen  and then having blood restored to the heart quickly when the bypass surgery is done. Tissue damage may be caused when the supply of oxygen is restored to the heart. There are sound biological reasons but limited data that shows that by giving a high dose of a statin drug it is believed that the injury to the heart may be lessened.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
The Flats G5 - Rooms 3 and 4
Flinders Drive
BEDFORD PARK SA 5042</ethicaddress>
      <ethicapprovaldate>19/12/2012</ethicapprovaldate>
      <hrec>378.12</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Joseph Selvanayagam</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
Flinders Drive
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Christine Edwards</name>
      <address>SAHMRI
Mark Oliphant Building
Box 15
Laffer Drive, Science Park
Bedford Park SA 5042 
</address>
      <phone>+61 8 8201 5656</phone>
      <fax>+61 8 8201 7701</fax>
      <email>christine.edwards@sahmri.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Joseph Selvanayagam</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
Flinders Drive
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Christine Edwards</name>
      <address>SAHMRI
Mark Oliphant Building
Box 15
Laffer Drive, Science Park
Bedford Park SA 5042 </address>
      <phone>+61 8 8201 5656</phone>
      <fax>+61 8 8201 7701</fax>
      <email>christine.edwards@sahmri.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>